Communiqués IRLAB Therapeutics AB

Actions

IRLAB A

SE0012675361

Produits pharmaceutiques

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 11/06/2026			Varia. 5j.	Varia. 1 janv.
1,268 ^SEK	+2,42%		-1,55%	-35,63%

08/06	Irlab négocié ce jour sur le Nasdaq Stockholm hors droit de souscription dans le cadre de son augmentation de capital	FW
05/06	IRLAB Therapeutics AB annonce la composition de son conseil d'administration, effective au 5 juin 2026	CI

Communiqués

05/06	IRLAB publishes information document in connection with the rights issue and announces that additional subscription undertakings have been received	AQ
05/06	Report from the Extraordinary General Meeting of IRLAB Therapeutics AB	AQ
03/06	IRLAB Participates at Aktiedagarna in Stockholm on June 9	AQ
03/06	IRLAB participates at Aktiedagarna in Stockholm on June 9.	AQ
06/05	IRLAB Therapeutics : Financial Report (irlab q1 2026 eng final)	PU
06/05	IRLAB Therapeutics : publishes interim report for the period January – March 2026	PU
06/05	IRLAB publishes interim report for the period January - March 2026	AQ
05/05	IRLAB resolves on a rights issue of approximately SEK 68 million with an overallotment issue and obtains extended loan financing	AQ
30/04	IRLAB: Invitation to the interim report for Q1 2026 presentation and webcast	AQ
29/04	IRLAB publishes the Annual Report for 2025	AQ
17/04	Nomination Committee's proposal to the Board of Directors for IRLAB Therapeutics' Annual General Meeting 2026	AQ
17/04	Nomination Committee’s proposal to the Board of Directors for IRLAB Therapeutics’ Annual General Meeting 2026	AQ
09/04	IRLAB to present at Redeye Healthcare Day 2026	AQ
17/03	IRLAB to Present Clinical and Preclinical Data at The AD/PD(TM) 2026 - 20th International Conference on Alzheimer's & Parkinson's Diseases	AQ
17/03	IRLAB to present clinical and preclinical data at the AD/PD™ 2026 – 20th International Conference on Alzheimer’s & Parkinson’s Diseases	AQ
02/03	IRLAB participates in Life Science Day in Gothenburg on March 4, 2026	AQ
26/02	IRLAB secures milestone payment for first patient dosed in Phase Ib study with IRL757 in Parkinson’s Disease	AQ
25/02	IRLAB Therapeutics : Financial Report (irlab year end report 2025 jan dec eng final)	PU
25/02	IRLAB publishes full-year report for the period January – December 2025	AQ
20/02	IRLAB has received scientific advisory board confirmation on next steps for pirepemat	AQ
18/02	IRLAB: Invitation to the year-end report 2025 presentation and webcast	AQ
19/01	IRLAB enters collaboration agreement with Danish biotech company Biomia ApS applying the Integrative Screening Process (ISP)	AQ
24/12	IRLAB Receives Approval for a Phase Ib Study with IRL757 in Parkinson's Disease	AQ
23/12	IRLAB Receives Approval for a Phase Ib Study with IRL757 in Parkinson’s Disease	AQ
11/12	The European Patent Office intends to grant a new patent for IRLAB’s mesdopetam.	AQ